Stockscreener 앱 받기
0.8469
4.31%
-0.0381
시장 영업 전:
.85
0.0031
+0.37%
전일 마감가:
$0.885
열려 있는:
$0.91
하루 거래량:
89,451
Relative Volume:
0.46
시가총액:
$3.08M
수익:
-
순이익/손실:
$-11.28M
주가수익비율:
-0.2814
EPS:
-3.01
순현금흐름:
$-9.78M
1주 성능:
-9.81%
1개월 성능:
-23.01%
6개월 성능:
-62.19%
1년 성능:
-88.41%
1일 변동 폭
$0.84
$0.93
1주일 범위
$0.84
$0.94
52주 변동 폭
$0.756
$7.651
Ensysce Biosciences Inc Stock (ENSC) Company Profile
명칭
Ensysce Biosciences Inc
전화
(858) 263-4196
주소
7946 IVANHOE AVENUE, LA JOLLA
ENSC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.8469 | 3.21M | 0 | -11.28M | -9.78M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Rate Hike: Will The Western Union Company benefit from geopolitical trendsBond Market & Fast Gain Stock Tips - baoquankhu1.vn
Merger Talk: Is Ensysce Biosciences Inc stock showing strong momentumQuarterly Trade Summary & Low Risk Investment Opportunities - baoquankhu1.vn
Ensysce Biosciences receives patent allowance in Brazil for pain tech By Investing.com - Investing.com Canada
Ensysce Biosciences receives patent allowance in Brazil for pain tech - Investing.com
New Brazil patent backs Ensysce bid for safer opioid pain drugs - Stock Titan
Volume Recap: Is Ensysce Biosciences Inc stock dividend yield sustainableTrade Exit Report & Low Risk High Win Rate Picks - Bộ Nội Vụ
Panic Selling: Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Big Picture & Detailed Earnings Play Strategies - Bộ Nội Vụ
What sentiment indicators say about Ensysce Biosciences Inc. stockBreakout Watch & Stock Portfolio Risk Management - ulpravda.ru
Ensysce Biosciences Annual Meeting: Share Issuance Approved, PF614 Phase III and FDA Designations Update - Defense World
Why Ensysce Biosciences Inc. stock is seen as undervaluedJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Why Ensysce Biosciences Inc. stock could be next big winnerWeekly Trade Report & AI Forecasted Stock Moves - Улправда
Ensysce Biosciences Shareholders Approve Key Corporate Actions - TipRanks
How Ensysce Biosciences Inc. stock compares to growth peersWeekly Gains Report & Safe Capital Growth Stock Tips - Улправда
How rising interest rates impact Ensysce Biosciences Inc. stockJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
Can Ensysce Biosciences Inc. stock resist market sell offsQuarterly Risk Review & Step-by-Step Trade Execution Guides - Улправда
MarketsMedicine Hat News - FinancialContent
New ADHD drug designed to deter abuse and overdose wins EU patent - Stock Titan
How Ensysce Biosciences Inc. stock reacts to Fed rate cutsSell Signals and Alerts & Low Cost Trading Plans - Улправда
Ensysce Biosciences, Inc.Common Stock (NQ: ENSC - FinancialContent
ENSC: All proposals passed and clinical programs advanced, setting the stage for a pivotal year - TradingView — Track All Markets
Ensysce’s PF614 Steps Forward in Phase 3 Post-Surgery Pain Trial: What Investors Should Watch - TipRanks
Ensysce Biosciences Issues Annual Shareholder Letter - The Globe and Mail
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid By Investing.com - Investing.com India
Ensysce Biosciences advances phase 3 trial for abuse-resistant opioid - Investing.com
Inside a biotech developing pain pills with built-in overdose protection - Stock Titan
Ensysce Biosciences Secures $4M Financing for PF614 - MSN
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 188.9% in December - Defense World
Will Ensysce Biosciences Inc. stock maintain growth storyWeekly Profit Recap & Free Community Supported Trade Ideas - Улправда
Ensysce Biosciences’ Innovative Approach to Safer Opioid Use: A Clinical Study Update - MSN
Why Ensysce Biosciences Inc. stock is considered a top pick2025 Trading Volume Trends & Weekly Stock Breakout Alerts - Улправда
How buybacks impact Ensysce Biosciences Inc. stock valueEarnings Performance Report & Community Shared Stock Ideas - Улправда
Can Ensysce Biosciences Inc. stock maintain operating margins2025 AllTime Highs & Verified Stock Trade Ideas - Улправда
Resistance Check: Can Ensysce Biosciences Inc. stock maintain operating marginsMarket Performance Report & High Return Trade Guides - Улправда
Ensysce Biosciences Earnings Notes - Trefis
EBIT per share of Ensysce Biosciences Inc. – OTC:ENSCW - TradingView — Track All Markets
ENSC enrolls first patient in critical phase 3 trial - MSN
Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614 - MSN
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial - Investing.com Australia
Should You Buy Ensysce Biosciences After Share Sale? - StocksToTrade
Is Ensysce Biosciences a Hidden Gem? - timothysykes.com
Ensysce Biosciences enrolls first patient in phase 3 pain drug trial By Investing.com - Investing.com South Africa
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid - Corsicana Daily Sun
Ensysce Biosciences (NASDAQ: ENSC) starts Phase 3 PF614 trial in abuse-deterrent opioid - Stock Titan
How Ensysce Biosciences Inc. stock performs in interest rate cyclesQuarterly Profit Review & Real-Time Buy Signal Notifications - Newser
Why Ensysce Biosciences Inc. stock attracts high net worth investorsIPO Watch & Free Weekly Chart Analysis and Trade Guides - Newser
Ensysce (NASDAQ: ENSC) secures MPAR overdose tech patent protection to 2042 - Stock Titan
Ensysce Biosciences Inc (ENSC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):